Mesure de l'incidence de l'hépatite virale B selon la séroconversion pour l'AC HBC, chez les donneurs de sang du Québec

Authors: Traoré, Aïcha Nina
Advisor: Germain, MarcMaunsell, Elizabeth
Abstract: The goal of this study was to evaluate the residual risk of hepatitis B viral (HBV) by measuring its incidence among 112,242 blood donors at Hema-Quebec, via the seroconversion for the antibody directed against the core (anti-HBc) instead of the usual surface antigen (HBsAg). We considered as incident cases donors who had a seroconversion for the anti-HBc and who were screened positive for the anti-HBs (antibody directed against the HBsAg). From April 2003 to April 2005, the identification of 13 anti-HBc incident cases and 3 for HBsAg permitted us to estimate respective incidences of 12.6 x 105 person-years-1 and 3.35 x 105 person-years-1, which corresponded to residual risks of 1 in 63,018 donations and 1 in 237,731 donations. The HBV incidence via the anti-HBc seroconversion is different from the estimate via the HBsAg. Our study suggests that anti-HBc seroconversion may not be a reliable marker of recent hepatitis B infection.
Document Type: Mémoire de maîtrise
Issue Date: 2007
Open Access Date: 12 April 2018
Grantor: Université Laval
Collection:Thèses et mémoires

Files in this item:
Description SizeFormat 
24027.pdfTexte608.7 kBAdobe PDFThumbnail
All documents in CorpusUL are protected by Copyright Act of Canada.